First‑Line Treatment Recommendations for Helicobacter pylori Infection

Empiric First‑Line Regimens

• Bismuth‑based quadruple therapy (PPI + bismuth + metronidazole + tetracycline) for 14 days is the preferred empiric regimen, especially in regions with high dual resistance to clarithromycin and metronidazole, and it retains acceptable eradication rates even when metronidazole‑resistant strains are present. 1
• Concomitant (non‑bismuth) quadruple therapy (PPI + amoxicillin + metronidazole + clarithromycin) for 14 days is an acceptable alternative when bismuth is unavailable and local clarithromycin resistance is high. 2

Consensus Endorsements

• The Toronto, Maastricht V/Florence, and American College of Gastroenterology (ACG) consensus groups all endorse bismuth quadruple therapy as the first‑line option for H. pylori eradication. 1

When Clarithromycin‑Based Triple Therapy May Still Be Used

• Triple therapy (PPI + clarithromycin + amoxicillin) is permissible only if local clarithromycin resistance is < 15 %, local eradication rates with this regimen exceed 85 %, or the patient originates from a low‑resistance area and has had no prior macrolide exposure. 3

Treatment Duration

• All first‑line regimens should be administered for 14 days to maximize initial success and reduce retreatment costs and microbiome disruption. 1

Penicillin‑Allergy Considerations

• In patients with a confirmed penicillin allergy, bismuth quadruple therapy should be used as the first‑line regimen. 1
• After first‑line failure in penicillin‑allergic patients, referral for allergy testing is advised because most reported penicillin allergies are not true allergies. 4

Second‑Line (Rescue) Treatment After First‑Line Failure

General Principle

• Do not reuse clarithromycin or levofloxacin if they were part of the prior regimen. 1

Regimen Selection

• If the first‑line regimen contained clarithromycin, choose either (a) bismuth quadruple therapy for 14 days or (b) levofloxacin triple therapy (PPI + amoxicillin + levofloxacin) for 14 days. 1
• If the first‑line regimen was bismuth quadruple or metronidazole‑containing, use levofloxacin triple therapy for 14 days. 1

Resistance Considerations

• Levofloxacin resistance is rapidly increasing; therefore, susceptibility testing should be strongly considered before selecting levofloxacin‑based rescue therapy. 1

Third‑Line (Salvage) Treatment After Two Failures

• Culture with antimicrobial susceptibility testing is strongly recommended after second‑line failure, although it may not be widely available in North America. 1

Empiric Options (when susceptibility data are unavailable)

• High‑dose dual therapy: high‑dose PPI (80 mg twice daily) plus high‑dose amoxicillin (2–3 g daily divided 3–4 times) for 14 days. 1
• Bismuth quadruple therapy (if not previously used) for 14 days. 1
• Concomitant therapy (PPI + amoxicillin + metronidazole + clarithromycin) when high dual clarithromycin/metronidazole resistance is present. 1

Fourth‑Line Treatment (After Three Failures)

• Rifabutin‑containing regimen (PPI + amoxicillin + rifabutin) for 14 days should be reserved for patients who have failed at least three prior regimens because of the risk of myelotoxicity. 3

Antibiotic Stewardship Principles

• Never reuse clarithromycin after prior exposure; resistance develops rapidly. 5
• Never reuse levofloxacin after prior exposure; resistance develops rapidly. 5
• Metronidazole may be reused when combined with bismuth because of synergistic effects. 1
• Amoxicillin and tetracycline can generally be reused because resistance to these agents remains rare. 1

Proton‑Pump Inhibitor (PPI) Administration Guidelines

• PPIs should be taken 30 minutes before meals on an empty stomach. 6
• Concomitant use of H₂‑receptor antagonists should be avoided. 6

Paradigm Shifts and Historical Context

• Recent guidelines (2022 Annual Review of Medicine; 2019 consensus) recommend abandoning empiric clarithromycin, metronidazole, and levofloxacin triple therapies due to rising antimicrobial resistance. 5
• In the 1990s, 7–10‑day triple regimens achieved ~90 % eradication, but success rates have declined substantially, prompting the shift to 14‑day quadruple regimens. 2

Common Pitfalls to Avoid

• Do not use 7–10‑day regimens; a 14‑day duration is now standard for all first‑line and rescue therapies. 1
• Do not use clarithromycin empirically unless local resistance is documented to be < 15 %. 5
• Do not use levofloxacin as first‑line therapy; reserve it for rescue after failure of other regimens. 2
• Do not repeat the same antibiotic combination that previously failed. 1

Guideline Recommendations for Helicobacter pylori Eradication Therapy

First‑Line Regimens

• Bismuth quadruple therapy (PPI + bismuth + tetracycline + metronidazole) for 14 days is the preferred initial regimen in North America, achieving high eradication rates even where clarithromycin and metronidazole resistance are common. Recommended by the Toronto, Maastricht V/Florence, and American College of Gastroenterology consensus groups. 7

• Dosage for the preferred bismuth quadruple regimen (based on the Annual Review of Medicine):

• Rifabutin‑based triple therapy (rifabutin + amoxicillin + high‑dose PPI) for 14 days is an acceptable empiric alternative for patients without a penicillin allergy. [7][8]

• Clarithromycin‑based triple therapy (PPI + clarithromycin + amoxicillin) should be used only when the patient has no prior macrolide exposure; otherwise it is discouraged because of rapid resistance development. 7

• Empiric clarithromycin use is not recommended in most North American settings due to widespread resistance. 8

Proton‑Pump Inhibitor (PPI) Selection

• Pantoprazole should be avoided because it has significantly lower acid‑suppression potency compared with other PPIs. 8

• Preferred PPIs (in order of potency), each given 20‑40 mg twice daily (approximately equivalent to the listed omeprazole doses):

• Administration details: PPIs should be taken 30 minutes before meals on an empty stomach, and concomitant H₂‑receptor antagonists should be avoided. 8

Second‑Line (Rescue) Therapy

• Never reuse clarithromycin or levofloxacin if they were part of a failed regimen, as resistance emerges rapidly. 7

• After failure of a clarithromycin‑based first‑line regimen, the preferred rescue options are:

• After failure of a bismuth‑quadruple or metronidazole‑containing regimen, levofloxacin triple therapy for 14 days is recommended, but susceptibility testing should be strongly considered because levofloxacin resistance is increasing. 7

• Fourth‑line rifabutin‑containing regimen (PPI + amoxicillin + rifabutin) for 14 days is reserved for patients who have failed at least three prior regimens, given the risk of myelotoxicity. 7

Special Populations

• Patients with confirmed penicillin allergy should receive bismuth quadruple therapy (tetracycline + metronidazole‑based) as first‑line treatment. 7

Antibiotic Stewardship Principles

• Never reuse after prior exposure:

• May reuse when resistance remains low:

Treatment Duration

• All major guidelines now endorse 14‑day regimens for both first‑line and rescue therapies to maximize eradication success and limit retreatment costs and microbiome disruption. The shift from 7‑10 day courses reflects declining efficacy of shorter courses amid rising antibiotic resistance. 7

Common Pitfalls to Avoid

• Do not use 7‑10 day regimens; 14 days is the standard.
• Do not employ clarithromycin empirically unless local resistance is documented to be <15 %. 8
• Do not use levofloxacin as a first‑line agent; reserve it for rescue therapy.
• Do not repeat any antibiotic combination that previously failed. 7
• Do not use pantoprazole when higher‑potency PPIs are available. 8
• Do not employ obsolete regimens (concomitant, sequential, hybrid therapies) that add unnecessary antibiotics and promote resistance. 8

Guideline Recommendations for Helicobacter pylori Eradication in Patients with Tuberculosis

First‑Line Therapy

• Bismuth quadruple therapy for 14 days is the preferred first‑line regimen for H. pylori eradication in patients receiving or who have received anti‑TB treatment, because it avoids rifamycin exposure and achieves high cure rates. (American College of Gastroenterology, strong recommendation) 9

Avoidance of Specific Regimens

• Clarithromycin‑based triple therapy should be avoided unless local clarithromycin resistance is < 15 % and the patient has never been exposed to macrolide antibiotics, to prevent treatment failure. (American College of Gastroenterology, conditional recommendation) [9][10]
• Clarithromycin or levofloxacin must not be reused if they were part of a previously failed regimen, as resistance can develop rapidly. (American College of Gastroenterology, strong recommendation) 11

Timing Relative to Anti‑TB Therapy

• H. pylori eradication can be administered concurrently with standard anti‑TB drugs using bismuth quadruple therapy, since no clinically significant drug interactions have been identified between bismuth, tetracycline, metronidazole and first‑line TB medications. (American College of Gastroenterology, strong recommendation) 9

Required Treatment Duration

• All H. pylori regimens in TB patients must be given for 14 days; shorter 7‑ to 10‑day courses are associated with inadequate cure rates. (American College of Gastroenterology, strong recommendation) [9][10]

Efficacy of Concomitant Therapy as First‑Line Treatment

Effectiveness

• In recent United States data, concomitant therapy (proton‑pump inhibitor + amoxicillin + clarithromycin + metronidazole) achieved an 89.8 % Helicobacter pylori eradication rate, which is nearly equivalent to the success of bismuth quadruple therapy, but it exposes patients to additional antibiotics when resistance to clarithromycin or metronidazole is present. 12

First‑Line and Rescue Treatment Recommendations for Helicobacter pylori Infection

First‑Line Regimens

• Bismuth quadruple therapy (PPI + bismuth + tetracycline + metronidazole) for 14 days is the preferred first‑line regimen for adult H. pylori infection, endorsed by the Toronto Consensus, Maastricht V/Florence consensus, and the American College of Gastroenterology. 13
• The regimen achieves high eradication rates even in regions with dual clarithromycin‑ and metronidazole‑resistance, and retains acceptable efficacy against metronidazole‑resistant strains because of the synergistic effect of bismuth. 13
• Concomitant quadruple therapy (PPI + amoxicillin + metronidazole + clarithromycin) for 14 days is an acceptable alternative when bismuth is unavailable and local clarithromycin resistance is high; U.S. data report an 89.8 % eradication rate, comparable to bismuth quadruple therapy. 13
• Clarithromycin‑based triple therapy (PPI + clarithromycin + amoxicillin) should be used only if (1) local clarithromycin resistance is < 15 %, (2) local eradication rates with this regimen exceed 85 %, and (3) the patient has never been exposed to macrolide antibiotics; it is discouraged in most North American settings. 13

Treatment Duration

• All first‑line regimens must be administered for 14 days to maximize initial success, reduce retreatment costs, and limit microbiome disruption; the shift from 7–10‑day courses reflects declining efficacy amid rising antibiotic resistance. 13

Rescue (Second‑Line) Therapy After First‑Line Failure

• Never reuse clarithromycin or levofloxacin if they were part of a failed regimen, because resistance develops rapidly. 13
• If the failed first‑line regimen contained clarithromycin, the preferred rescue is bismuth quadruple therapy for 14 days; levofloxacin triple therapy (PPI + amoxicillin + levofloxacin) for 14 days is an alternative. 13
• If the failed first‑line regimen was bismuth quadruple or otherwise contained metronidazole, levofloxacin triple therapy for 14 days is recommended, with strong consideration of susceptibility testing before levofloxacin use due to increasing resistance. 13

Antibiotic Stewardship Principles

• Metronidazole, amoxicillin, and tetracycline may be reused because resistance to these agents remains rare (metronidazole benefits from synergism with bismuth). 13
• Clarithromycin and levofloxacin should be avoided for reuse after prior exposure because of rapid resistance development. 13

Proton Pump Inhibitor (PPI) Selection and Administration

• Higher‑potency PPIs are preferred (esomeprazole > rabeprazole > lansoprazole > omeprazole); pantoprazole should be avoided due to lower acid‑suppression potency. 13
• PPIs must be taken 30 minutes before meals on an empty stomach, and H₂‑receptor antagonists (e.g., famotidine) must not be used concurrently because they interfere with PPI activation. 13

Eradication Confirmation

• All patients should undergo eradication testing after completing therapy; current practice shows only 50–64 % receive confirmation testing, which is suboptimal. 13

Guideline‑Recommended Management of Helicobacter pylori Infection

First‑Line Empiric Therapy

• Bismuth quadruple therapy (PPI + bismuth + tetracycline + metronidazole) for 14 days is the preferred first‑line regimen for H. pylori infection in North America. The regimen includes tetracycline 500 mg four times daily, metronidazole 500 mg three‑to‑four times daily, a standard‑dose PPI twice daily, and bismuth subsalicylate 262 mg four times daily. 14
• Eradication rates exceed 85 % even in regions with dual clarithromycin‑ and metronidazole‑resistance, because bismuth synergizes with metronidazole to overcome resistance. 15
• The Toronto Consensus, Maastricht V/Florence Consensus, and the American College of Gastroenterology endorse bismuth quadruple therapy as the preferred empiric first‑line regimen. 15

Alternative First‑Line Options

• Rifabutin triple therapy (PPI + amoxicillin + rifabutin) for 14 days is an acceptable empiric alternative for patients without a penicillin allergy, given the rarity of rifabutin and amoxicillin resistance. 14
• Concomitant quadruple therapy (PPI + amoxicillin + metronidazole + clarithromycin) for 14 days may be used when bismuth is unavailable and local clarithromycin resistance is high; recent U.S. data show approximately 90 % eradication. 15
• Clarithromycin‑based triple therapy (PPI + clarithromycin + amoxicillin) should be avoided in most North American settings; it is only considered when local clarithromycin resistance is < 15 % and eradication rates exceed 85 % in patients without prior macrolide exposure. [14][15]

Proton‑Pump Inhibitor (PPI) Selection

• Rabeprazole 20 mg twice daily is the most potent preferred PPI for H. pylori regimens. 14
• Lansoprazole 30 mg twice daily is an acceptable alternative with slightly lower potency. 14
• Omeprazole 20 mg twice daily is the least preferred among the acceptable PPIs. 14
• PPIs must be taken 30 minutes before meals on an empty stomach to achieve maximal acid suppression. 14

Rescue (Second‑Line) Therapy After First‑Line Failure

• Never reuse clarithromycin or levofloxacin if they were part of a previously failed regimen, because resistance develops rapidly after exposure. [14][15]

• If the failed first‑line regimen contained clarithromycin, the preferred second‑line option is bismuth quadruple therapy for 14 days; levofloxacin triple therapy (PPI + amoxicillin + levofloxacin 500 mg daily) for 14 days is an alternative. [14][15]

• If the failed first‑line regimen was bismuth quadruple or included metronidazole, levofloxacin triple therapy for 14 days is recommended, with strong consideration of susceptibility testing before levofloxacin use due to rising resistance. 14

• High‑dose dual therapy (high‑potency PPI + amoxicillin 2–3 g daily divided 3–4 times) for 14 days achieves approximately 89 % eradication and is an effective second‑line option. 14

Third‑Line (Salvage) Therapy

• Culture with antimicrobial susceptibility testing is strongly recommended after second‑line failure, although availability is limited in North America. 14

• When susceptibility data are unavailable, empiric high‑dose dual therapy (PPI 80 mg twice daily + amoxicillin 2–3 g daily divided 3–4 times) for 14 days is a viable third‑line regimen. 14

• Bismuth quadruple therapy for 14 days may be used as a third‑line option if it has not been previously administered. 14

Fourth‑Line Therapy

• A rifabutin‑containing regimen (PPI + amoxicillin + rifabutin 150–300 mg daily) for 14 days should be reserved for patients who have failed at least three prior regimens, because of the risk of myelotoxicity. [14][15]
• Rifabutin can be prescribed without prior susceptibility testing, as resistance to rifabutin and amoxicillin remains rare. 14

Antibiotic Stewardship Principles

• Metronidazole may be reused when combined with bismuth, owing to synergistic effects that overcome metronidazole resistance. 14
• Amoxicillin and tetracycline can be reused because resistance to these agents remains rare. 14

Treatment Duration

• All first‑line and rescue regimens must be administered for 14 days to maximize eradication success, reduce retreatment costs, and limit microbiome disruption. [14][15]

Common Pitfalls to Avoid

• Do not use 7–10‑day regimens; a 14‑day duration is now the universal standard for all H. pylori therapies. [14][15]
• Do not use clarithromycin empirically unless local resistance is < 15 % and the patient has never received a macrolide. [14][15]
• Do not use levofloxacin as a first‑line agent; reserve it for rescue after failure of other regimens. [14][15]
• Do not repeat the same antibiotic combination that previously failed. 14

Key Factors for Successful Eradication

• Use bismuth quadruple therapy as the first‑line regimen.
• Ensure a 14‑day treatment duration.
• Select a high‑potency PPI (rabeprazole > lansoprazole > omeprazole).
• Confirm eradication after therapy (e.g., urea breath test).
• Avoid reuse of clarithromycin or levofloxacin after prior exposure. [14][15]

Bismuth Quadruple Therapy as the Preferred First‑Line Regimen for Helicobacter pylori Infection

First‑Line Treatment Recommendations

• The Toronto Consensus, Maastricht V/Florence Consensus, and American College of Gastroenterology endorse a 14‑day bismuth quadruple regimen (PPI + bismuth + tetracycline + metronidazole) as the preferred first‑line therapy for adults, achieving >85 % eradication even when dual clarithromycin‑ and metronidazole‑resistance is present. 16
• When bismuth is unavailable, a 14‑day concomitant quadruple regimen (PPI + amoxicillin + metronidazole + clarithromycin) is acceptable; U.S. data show an 89.8 % eradication rate. 16
• Clarithromycin‑based triple therapy should be reserved for regions where local clarithromycin resistance is <15 %, eradication rates exceed 85 %, and the patient has never received a macrolide; otherwise it is discouraged in North America. 16
• All first‑line regimens must be administered for 14 days to maximize eradication, reduce retreatment costs, and limit microbiome disruption. 16

Diagnostic Testing (Non‑Invasive)

• Urea breath testing is the preferred non‑invasive method for detecting active infection, offering high sensitivity and specificity. 17
• Stool antigen testing is an acceptable alternative when urea breath testing is unavailable or impractical. 17
• Serologic IgG testing is not recommended for routine diagnosis because antibodies persist after eradication; it should only be used in patients with very high pre‑test probability and must be confirmed with urea breath or stool antigen testing. 18

Diagnostic Testing (Invasive)

• When endoscopy is performed, histology with H. pylori‑specific immunohistochemistry provides the most accurate invasive diagnosis. 19

Pre‑Test Medication Management

• Proton‑pump inhibitors must be stopped 1–2 weeks before urea breath, stool antigen, or biopsy‑based testing to avoid false‑negative results. 18

Indications for Testing (High‑Evidence)

• Testing is strongly recommended (100 % expert agreement) for individuals with active or past gastric/duodenal ulcer, uninvestigated dyspepsia, gastric MALT lymphoma, or a family history of gastric cancer. 20
• Additional strong indications include first‑generation immigrants from high‑prevalence regions, high‑risk racial/ethnic groups in the United States (Latino, African‑American, East‑Asian) with 2.6–3.2‑fold higher prevalence, household contacts of confirmed cases, and chronic NSAID or aspirin users. 20

Emerging Consensus on Eradication

• Approximately 40 % of current guidelines advise eradication of H. pylori infection regardless of symptom status once infection is confirmed, recognizing the condition as an infectious disease without proven host benefit. 20

Antibiotic Stewardship Principles

• Clarithromycin and levofloxacin must never be reused after prior exposure because resistance develops rapidly. 16
• Metronidazole may be reused when combined with bismuth (synergistic effect overcomes resistance), and amoxicillin and tetracycline can be reused because resistance to these agents remains rare. 16

Rescue (Second‑Line) Therapy After First‑Line Failure

• If the failed first‑line regimen contained clarithromycin, the preferred rescue is 14‑day bismuth quadruple therapy; levofloxacin‑based triple therapy is an alternative. 16
• If the failed regimen was bismuth quadruple or included metronidazole, levofloxacin‑based triple therapy for 14 days is recommended, with susceptibility testing strongly considered before levofloxacin use. 16

Third‑Line (Salvage) Strategy

• After two treatment failures, culture with antimicrobial susceptibility testing is strongly recommended to guide therapy. 16

Fourth‑Line Therapy

• A rifabutin‑containing regimen (PPI + amoxicillin + rifabutin) for 14 days should be reserved for patients who have failed at least three prior regimens; resistance to rifabutin and amoxicillin remains rare. 16

Avoidance of Suboptimal Practices

• Do not use 7–10‑day courses; 14 days is now the universal standard for all H. pylori regimens. 16
• Do not employ clarithromycin empirically unless local resistance is documented <15 % and the patient has never received a macrolide. 16
• Do not use levofloxacin as a first‑line agent; it should be reserved for rescue therapy after other regimens have failed. 16
• Do not perform diagnostic testing without a plan to treat, as H. pylori gastritis is recognized as an infectious disease that should be eradicated when diagnosed. 20
• Do not rely on serology alone for treatment decisions; confirm active infection with urea breath or stool antigen testing. 18

Management of Resistant Helicobacter pylori Infection

General Principles

• Antibiotic resistance—not patient non‑adherence—is the primary driver of first‑line treatment failure.  [AGA Clinical Practice Update 2021] 21
• All salvage regimens must be administered for 14 days; shorter (7–10 day) courses result in unacceptably low eradication rates. [21][22]

Antibiotic Stewardship Rules

• Clarithromycin must never be reused after any prior exposure because resistance develops in > 90 % of previously treated strains. [21][22]
• Levofloxacin must not be reused after prior exposure; resistance emerges rapidly. [21][22]
• Metronidazole can be reused only when combined with bismuth, which synergistically overcomes in‑vitro resistance. [21][22]
• Amoxicillin and tetracycline may be reused because resistance remains < 5 % in most regions. [21][22]

Second‑Line Therapy (after first‑line failure)

Preferred Regimen (if not previously used)

• Bismuth quadruple therapy (high‑dose PPI + bismuth + tetracycline + metronidazole) for 14 days achieves 69–88 % eradication even in salvage settings and retains efficacy despite metronidazole resistance due to bismuth synergy. [21][22]

Alternative Regimen

• Levofloxacin triple therapy (high‑dose PPI + amoxicillin + levofloxacin) for 14 days yields ≈ 85 % eradication in salvage settings; however, regional levofloxacin resistance is 18–24 % (Europe/North America). Susceptibility testing is strongly advised before use. [21][22]

Third‑Line (Salvage) Strategies (after two regimen failures)

• Culture with antimicrobial susceptibility testing is strongly recommended to guide therapy, although availability may be limited. 22

• High‑dose dual therapy (high‑dose PPI + amoxicillin) for 14 days provides ≈ 89 % eradication in salvage settings (data from Taiwan). 22

• If dual therapy is unsuitable, bismuth quadruple therapy (if not previously used) remains an effective option. 22

• Tetracycline‑levofloxacin quadruple therapy (PPI + bismuth + tetracycline + levofloxacin) for 14 days achieved 98 % eradication versus 69 % for levofloxacin‑amoxicillin triple therapy in head‑to‑head trials. 22

Fourth‑Line Therapy (after ≥ 3 failures)

• Rifabutin triple therapy (high‑dose PPI + amoxicillin + rifabutin) for 14 days is reserved for fourth‑line use because rifabutin carries a risk of myelotoxicity. Resistance to rifabutin and amoxicillin remains < 2 %. 21

Special Populations & Considerations

• Penicillin‑allergic patients should undergo formal allergy testing; most reported allergies are not IgE‑mediated, allowing safe use of amoxicillin. 21
• In confirmed penicillin allergy, the bismuth quadruple regimen (tetracycline‑metronidazole based) is the preferred option. 22

Diagnostic Follow‑Up

• A test‑of‑cure (urea breath test or stool antigen) performed 4–6 weeks after completion of therapy is mandatory to confirm eradication.

All statements are derived from the 2021 AGA Clinical Practice Update and supported by the cited Gastroenterology literature.

Evidence‑Based Recommendations for Helicobacter pylori Treatment (Annual Review of Medicine 2022)

First‑Line Regimens

• Bismuth quadruple therapy (high‑potency PPI + bismuth subsalicylate 262 mg qid + tetracycline 500 mg qid + metronidazole 500 mg tid‑qid) given for 14 days is the preferred empiric regimen for adult H. pylori infection. 23
• Rifabutin triple therapy (rifabutin 150 mg bid + amoxicillin 1 g tid + high‑dose PPI 20‑40 mg bid) for 14 days is an acceptable empiric alternative for patients without a penicillin allergy. 23
• Clarithromycin‑based triple therapy may be used only when all of the following are met:

Proton‑Pump Inhibitor (PPI) Selection

• Higher‑potency PPIs markedly improve eradication outcomes, especially in amoxicillin‑containing regimens. 23
• Preferred PPIs (twice daily), listed by descending acid‑suppression potency:
  23
• Pantoprazole should be avoided because its acid‑suppression potency is substantially lower (40 mg pantoprazole ≈ 9 mg omeprazole). 23
• Pantoprazole must not be used when higher‑potency PPIs (e.g., esomeprazole, rabeprazole) are available. 23

Rescue and Fourth‑Line Therapy

• After failure of three or more regimens, a rifabutin‑containing regimen (high‑potency PPI + amoxicillin + rifabutin 150 mg bid) for 14 days is recommended as a last‑resort option; resistance to rifabutin and amoxicillin remains rare (< 2 %). 23

Pitfalls to Avoid

• Obsolete regimens (sequential, hybrid, reverse‑hybrid, or concomitant therapies that include ineffective antibiotics) should be avoided to limit the spread of antimicrobial resistance. 23

Key Success Factors

• Aim for cure rates ≥ 90‑95 % rather than merely demonstrating superiority over placebo.
• Implement feedback loops to monitor local resistance patterns and adapt therapy accordingly.
• Recognize that antibiotic resistance, not patient non‑adherence, is the primary driver of treatment failure. 23

Management of Helicobacter pylori Infection – Evidence‑Based Recommendations

1. First‑Line Therapy Selection

• Clarithromycin‑based triple therapy should be used only when (a) local clarithromycin resistance < 15 %, (b) local eradication rates with this regimen > 85 %, and (c) the patient has never received a macrolide; otherwise it is discouraged in North America where resistance reaches up to 30 %. – Gastroenterology guideline (2019) 24

2. Management of Patients with Reported Penicillin Allergy

• Referral for formal penicillin‑allergy testing is strongly advised after first‑line failure because most reported allergies are not true IgE‑mediated reactions. – Gastroenterology guideline (2019, 2021) [24][25]
• If testing confirms no true allergy, amoxicillin‑containing regimens can be used safely at a total daily dose of ≥ 2 g divided 3–4 times daily. – Gastroenterology guideline (2021) 25

3. Core Antibiotic‑Stewardship Principles

• Antibiotic resistance—not patient non‑adherence—is the primary driver of treatment failure. – Gastroenterology guideline (2021) 25
• Never reuse clarithromycin after any prior exposure; resistance develops in > 90 % of previously treated strains. – Gastroenterology guideline (2021) 25
• Never reuse levofloxacin after prior exposure; resistance emerges rapidly. – Gastroenterology guideline (2021) 25
• Metronidazole may be reused only when combined with bismuth, as the synergistic effect overcomes in‑vitro resistance. – Gastroenterology guideline (2021) 25
• Amoxicillin and tetracycline can be safely reused because resistance remains < 5 % in most regions. – Gastroenterology guideline (2021) 25

4. Second‑Line (Rescue) Therapy After First‑Line Failure

4.1 After Clarithromycin‑Containing First‑Line Regimen

• Bismuth quadruple therapy for 14 days is the preferred rescue option, achieving 69.3 % eradication in salvage settings. – Gastroenterology guideline (2021) 25
• Levofloxacin triple therapy (PPI + amoxicillin + levofloxacin 500 mg daily) for 14 days is an alternative; susceptibility testing is strongly advised because levofloxacin resistance in North America ranges from 18–24 %. – Gastroenterology guideline (2021) 25

4.2 After Bismuth Quadruple or Metronidazole‑Containing First‑Line Regimen

• Levofloxacin triple therapy for 14 days is recommended, with susceptibility testing before use due to rising resistance. – Gastroenterology guideline (2021) 25
• High‑dose dual therapy (high‑potency PPI 80 mg twice daily + amoxicillin 2–3 g daily divided 3–4 times) for 14 days achieves approximately 89 % eradication in salvage settings. – Gastroenterology guideline (2021) 25

5. Third‑Line (Salvage) Therapy After Two Failures

• Perform gastric culture with antimicrobial susceptibility testing after second‑line failure to guide subsequent therapy (when available). – Gastroenterology guideline (2021) 25
• If susceptibility data are unavailable, high‑dose dual therapy (PPI + amoxicillin as above) for 14 days is a viable empiric third‑line regimen. – Gastroenterology guideline (2021) 25
• Tetracycline‑levofloxacin quadruple therapy (PPI + bismuth + tetracycline + levofloxacin) for 14 days demonstrated 98 % eradication versus 69 % for levofloxacin‑amoxicillin triple therapy in head‑to‑head trials. – Gastroenterology guideline (2021) 25
• Bismuth quadruple therapy for 14 days may be used as a third‑line option if it has not been previously administered. – Gastroenterology guideline (2021) 25
• Concomitant therapy (PPI + amoxicillin + metronidazole + clarithromycin) for 14 days is acceptable when dual clarithromycin/metronidazole resistance is high, although evidence for salvage use is limited. – Gastroenterology guideline (2019) 24

6. Fourth‑Line Therapy (≥ Three Prior Failures)

• A rifabutin‑containing regimen (PPI + amoxicillin + rifabutin 150–300 mg daily) for 14 days should be reserved for patients who have failed at least three prior regimens because of the risk of myelotoxicity. – Gastroenterology guideline (2019, 2021) [24][25]
• The American College of Gastroenterology, Maastricht/Florence, and Toronto Consensus groups position rifabutin as at least third‑ or fourth‑line therapy due to potential myelotoxicity. – Gastroenterology guideline (2019) 24

All bullet points are derived from cited evidence and include the relevant citation identifier(s).

Guidelines for Managing Helicobacter pylori Infection – Evidence‑Based Recommendations (Cited)

Antibiotic Stewardship Principles

• Avoid reusing clarithromycin or levofloxacin after they have been part of a failed regimen, because resistance develops in >90 % of previously treated strains. (Gastroenterology, 2021) 26
• Metronidazole may be reused when combined with bismuth, as the synergistic effect overcomes metronidazole resistance. (Gastroenterology, 2021) 26
• Amoxicillin resistance remains low (<5 %) and can be safely reused in subsequent regimens. (Gastroenterology, 2021) 26
• Tetracycline resistance also remains low (<5 %). (Gastroenterology, 2021) 26

Rescue Therapy After First‑Line Failure

After Clarithromycin‑Containing First‑Line Failure

• Bismuth quadruple therapy (PPI + bismuth + tetracycline + metronidazole) for 14 days is the preferred rescue option, achieving a 69.3 % eradication rate in salvage settings. (Gastroenterology, 2021) 26
• Levofloxacin triple therapy (PPI + amoxicillin + levofloxacin 500 mg daily) for 14 days is an alternative; susceptibility testing is strongly advised because levofloxacin resistance in North America ranges from 18 % to 24 %. (Gastroenterology, 2021) 26

After Bismuth Quadruple or Metronidazole‑Containing First‑Line Failure

• Levofloxacin triple therapy for 14 days is recommended, with susceptibility testing strongly considered before use. (Gastroenterology, 2021) 26
• High‑dose dual therapy (high‑potency PPI 80 mg twice daily + amoxicillin 2–3 g daily divided 3–4 times) for 14 days achieves approximately 89 % eradication in salvage settings. (Gastroenterology, 2021) 26

Third‑Line (Salvage) Options After Two Failures

• Perform culture with antimicrobial susceptibility testing to guide therapy after second‑line failure. (Gastroenterology, 2021) 26
• Tetracycline‑levofloxacin quadruple therapy (PPI + bismuth + tetracycline + levofloxacin) for 14 days achieved 98 % eradication versus 69 % for levofloxacin‑amoxicillin triple therapy in head‑to‑head trials. (Gastroenterology, 2021) 26
• High‑dose dual therapy (PPI 80 mg twice daily + amoxicillin 2–3 g daily divided 3–4 times) for 14 days remains an effective empiric option. (Gastroenterology, 2021) 26
• Bismuth quadruple therapy for 14 days may be used if it has not been employed previously. (Gastroenterology, 2021) 26

Fourth‑Line Therapy (After ≥ Three Failures)

• A rifabutin‑containing regimen (PPI + amoxicillin + rifabutin 150–300 mg daily) for 14 days should be reserved for patients who have failed at least three prior regimens because of the risk of myelotoxicity. (Gastroenterology, 2021) 26
• Resistance to rifabutin and amoxicillin remains rare (<2 %). (Gastroenterology, 2021) 26

Confirmation of Eradication

• A test‑of‑cure (urea breath test or stool antigen) performed 4–6 weeks after completion of therapy is mandatory; proton‑pump inhibitors must be stopped 1–2 weeks before testing to avoid false‑negative results. (Gastroenterology, 2021) 26

2026 Helicobacter pylori Treatment Guidelines – Evidence‑Based Recommendations

First‑Line Empiric Therapy

• Bismuth quadruple therapy (PPI + bismuth + tetracycline + metronidazole) for 14 days is the preferred first‑line regimen, achieving >85 % eradication even in areas with dual clarithromycin‑ and metronidazole‑resistance. The regimen uses bismuth subsalicylate 262 mg (2 tablets) QID, tetracycline 500 mg QID, metronidazole 500 mg TID–QID, and a high‑potency PPI BID. [Annual Review of Medicine]27
• Consensus endorsement: The Toronto Consensus, Maastricht V/Florence Consensus, and the American College of Gastroenterology all recommend this regimen as the preferred first‑line option. [Gastroenterology][28][29]
• Rifabutin‑based triple therapy (PPI + amoxicillin + rifabutin) for 14 days is an acceptable empiric alternative for patients without a penicillin allergy; resistance to rifabutin and amoxicillin remains <2 %. [Annual Review of Medicine]27

Proton‑Pump Inhibitor (PPI) Selection

• Rabeprazole 20–40 mg BID is the most potent PPI (≈ 36 mg omeprazole equivalent). [Annual Review of Medicine]27
• Esomeprazole 20–40 mg BID (≈ 32 mg omeprazole equivalent). [Annual Review of Medicine]27
• Lansoprazole 30–45 mg BID (≈ 27 mg omeprazole equivalent). [Annual Review of Medicine]27
• Omeprazole 40 mg BID is the least preferred but acceptable option. [Annual Review of Medicine]27
• Pantoprazole should be avoided because 40 mg provides acid‑suppression comparable to only 9 mg omeprazole. [Annual Review of Medicine]27

Second‑Line (Rescue) Therapy

• Never reuse clarithromycin or levofloxacin after a regimen failure; resistance develops in >90 % of previously exposed strains. [Gastroenterology]30
• After clarithromycin‑containing first‑line failure:
  
  • Bismuth quadruple therapy for 14 days is the preferred rescue, achieving 69.3 % eradication in salvage settings. [Gastroenterology]30
  • Levofloxacin triple therapy (PPI + amoxicillin + levofloxacin) for 14 days is an alternative, but susceptibility testing is strongly advised because regional levofloxacin resistance ranges 18–24 %. [Gastroenterology]30
• After bismuth‑quadruple or metronidazole‑containing first‑line failure:
  
  • Levofloxacin triple therapy for 14 days is recommended, with susceptibility testing considered. [Gastroenterology]30
  • High‑dose dual therapy (high‑potency PPI 80 mg BID + amoxicillin 2–3 g/day divided 3–4 times) for 14 days yields ≈ 89 % eradication in salvage settings. [Gastroenterology]30

Third‑Line (Salvage) Therapy

• Culture with antimicrobial susceptibility testing is strongly recommended after second‑line failure to guide therapy, though availability may be limited in North America. [Gastroenterology][29][30]
• Empiric options when susceptibility data are unavailable:
  
  • High‑dose dual therapy (PPI + amoxicillin) for 14 days remains viable. [Gastroenterology]30
  • Tetracycline‑levofloxacin quadruple therapy (PPI + bismuth + tetracycline + levofloxacin) for 14 days achieved 98 % eradication versus 69 % for levofloxacin‑amoxicillin triple therapy in head‑to‑head trials. [Gastroenterology]30
  • Bismuth quadruple therapy for 14 days may be used if not previously administered. [Gastroenterology]30
  • Concomitant therapy (PPI + amoxicillin + metronidazole + clarithromycin) for 14 days is acceptable when dual clarithromycin/metronidazole resistance is high, though evidence for salvage use is limited. [Gastroenterology]29

Fourth‑Line Therapy (≥ 3 Prior Failures)

• Rifabutin‑containing regimen (PPI + amoxicillin + rifabutin 150–300 mg daily) for 14 days should be reserved for patients with ≥ 3 prior regimen failures because of myelotoxicity risk. [Gastroenterology]**[29][30] [Annual Review of Medicine]**27
• Resistance to rifabutin and amoxicillin remains rare (<2 %). [Gastroenterology]30 [Annual Review of Medicine]27

Antibiotic Stewardship Principles

• Metronidazole may be reused only when combined with bismuth, as the synergistic effect overcomes in‑vitro resistance. [Gastroenterology][29][30]
• Amoxicillin and tetracycline can be safely reused; resistance is <5 % in most regions. [Gastroenterology]30

Diagnostic Testing

• Urea breath test is the preferred non‑invasive method for detecting active infection, with sensitivity 88–95 % and specificity 95–100 %. [World Journal of Emergency Surgery]31
• Stool antigen testing is an acceptable alternative when urea breath testing is unavailable (sensitivity ≈ 94 %, specificity ≈ 92 %). [World Journal of Emergency Surgery]31
• Test‑of‑cure (urea breath test or stool antigen) should be performed 4–6 weeks after therapy completion and is mandatory to confirm eradication. [Gastroenterology]30

Drivers of Treatment Failure

• Antibiotic resistance—not patient non‑adherence—is the primary driver of H. pylori treatment failure. [Gastroenterology]30 [Clinical Gastroenterology and Hepatology]32

All bullet points are supported by the cited references indicated in brackets.

First‑Line 14‑Day Bismuth Quadruple Therapy for Helicobacter pylori Eradication

Recommended Regimen (Adult, No Drug Allergies)

• Bismuth quadruple therapy for 14 days—proton‑pump inhibitor (PPI) twice daily, bismuth subsalicylate 262 mg (2 tablets) four times daily, tetracycline 500 mg four times daily, and metronidazole 500 mg three‑to‑four times daily—is the preferred first‑line regimen. 33, 34

Dosing Details

Bismuth Subsalicylate

• 262 mg (2 tablets) taken four times daily, 30 min before meals and at bedtime. 34

Tetracycline

• 500 mg taken four times daily, 30 min after meals. 33, 34

Metronidazole

• 500 mg taken three to four times daily, 30 min after meals. 33, 34

Proton‑Pump Inhibitor (PPI)

• Any PPI given twice daily, 30 min before the morning and evening meals. 33, 34

PPI Selection (Order of Preference)

Preference based on potency and guideline endorsement. 34

Efficacy and Guideline Endorsement

• The regimen achieves >85–90 % eradication even in regions with high dual clarithromycin‑ and metronidazole‑resistance. 33, 34
• It is endorsed by all three major consensus groups (Toronto Consensus, Maastricht V/Florence Consensus, American College of Gastroenterology). 33
• Bismuth synergizes with metronidazole, preserving efficacy when in‑vitro metronidazole resistance is present. 33, 34
• Because the regimen does not rely on clarithromycin, it avoids the widespread clarithromycin resistance (up to ~30 % in North America) that has rendered clarithromycin‑based triple therapy obsolete. 33

Alternative First‑Line Options (When Bismuth Unavailable)

• Rifabutin triple therapy – high‑dose PPI + amoxicillin 1 g three times daily + rifabutin 150 mg twice daily for 14 days – is an acceptable empiric alternative for patients without a penicillin allergy. 34
• Resistance to rifabutin and amoxicillin remains rare (<2 %). 34

Critical Treatment Duration

• All first‑line regimens must be given for 14 days to maximize eradication success, reduce retreatment costs, and limit disruption of the gut microbiome. 33, 34
• The shift from 7–10‑day courses reflects declining efficacy amid rising antibiotic resistance. 33

Situations in Which Clarithromycin‑Based Triple Therapy Is Not Recommended

• Clarithromycin‑based triple therapy (PPI + clarithromycin + amoxicillin) should be used only when all of the following are met:
• In most North American settings, the regimen is discouraged because clarithromycin resistance is widespread. 33

Practical Pitfalls to Avoid

• Do not use 7–10‑day regimens; a 14‑day course is now the universal standard. 33
• Do not employ clarithromycin empirically unless the local resistance threshold (<15 %) and macrolide‑naïve status are confirmed. 33, 34
• Do not use levofloxacin as a first‑line agent; reserve it for rescue therapy after failure of other regimens. 33
• Do not use pantoprazole when higher‑potency PPIs (rabeprazole, esomeprazole, lansoprazole, omeprazole) are available. 34
• Ensure PPIs are taken 30 min before meals on an empty stomach and avoid concomitant H₂‑receptor antagonists (e.g., famotidine) because they interfere with PPI activation. 33, 34

Resistance as the Primary Driver of Failure

• Antibiotic resistance—not patient non‑adherence—is the main cause of treatment failure in H. pylori eradication. 34

Evidence‑Based Management of Helicobacter pylori Infection (Cited Facts)

1. Antimicrobial Resistance Landscape

• In most regions, resistance to tetracycline and amoxicillin remains <5 %. 35
• Resistance to clarithromycin exceeds 90 % in strains previously exposed to the drug. 35
• Resistance to levofloxacin emerges rapidly after prior exposure, with contemporary North American rates of 18–24 %. 35
• Metronidazole can be reused effectively when combined with bismuth, which synergistically overcomes metronidazole resistance. 35

2. First‑Line Therapy (Empiric)

• Bismuth quadruple therapy (high‑potency PPI + bismuth + tetracycline + metronidazole) for 14 days is the preferred empiric regimen, achieving >85 % eradication even in areas with high dual clarithromycin‑metronidazole resistance. (Guideline consensus cited, but specific citation not provided in the source; therefore omitted here.)

3. Rescue (Second‑Line) Therapy After First‑Line Failure

3.1 After Clarithromycin‑Containing First‑Line Failure

• Bismuth quadruple therapy for 14 days (if not previously used) yields an eradication rate of ~69 % in salvage settings. 35
• Levofloxacin triple therapy (high‑potency PPI + amoxicillin + levofloxacin 500 mg daily) for 14 days is an alternative; however, due to 18–24 % levofloxacin resistance, susceptibility testing is strongly advised before use. 35

3.2 After Bismuth or Metronidazole‑Containing First‑Line Failure

• Levofloxacin triple therapy for 14 days is recommended, with a strong recommendation for susceptibility testing. 35
• High‑dose dual therapy (high‑potency PPI 80 mg twice daily + amoxicillin 2–3 g daily divided 3–4 times) for 14 days achieves an ≈89 % eradication rate. 35

4. Third‑Line (Salvage) Therapy After Two Failures

• Culture with antimicrobial susceptibility testing is strongly recommended to guide therapy, although availability may be limited. 35

Empiric Options When Susceptibility Data Unavailable

All figures derived from head‑to‑head trials. 35

5. Fourth‑Line Therapy (After ≥ 3 Failures)

• Rifabutin‑containing regimen (high‑potency PPI + amoxicillin + rifabutin 150–300 mg daily) for 14 days should be reserved for patients with ≥ 3 prior regimen failures because of the risk of myelotoxicity. 35
• Resistance to rifabutin and amoxicillin remains <2 %, allowing use without prior susceptibility testing. 35

6. Antibiotic Stewardship Principles

All stewardship statements are supported by the 2021 Gastroenterology evidence review. 35

7. Management of Patients with Reported Penicillin Allergy

• After first‑line failure, formal penicillin allergy testing is strongly advised because most reported allergies are not true IgE‑mediated reactions. 35
• If testing confirms the absence of a true allergy, amoxicillin‑containing regimens can be safely employed. 35

8. Primary Driver of Treatment Failure

• Antibiotic resistance, rather than patient non‑adherence, is the principal cause of H. pylori treatment failure. 35